Keya Medical
科亚医疗
Keya Medical is a Chinese medical AI company and a portfolio company of Source Code Capital . Its flagship product is DeepVessel FFR (DVFFR), a CT-based fractional flow reserve analysis system that in 2022 became the world's first CT-FFR product to hold regulatory certifications from all three major markets—China's NMPA (granted January 2020), the EU's CE mark (August 2018), and the US FDA's 510(k) clearance—enabling its commercial launch in the United States . The company was founded by Ma Hui, and Source Code Capital partner Yungang Huang was among its investors, with the firm recognizing the deal as part of its digital healthcare track record .
AI-generated — may contain errors, please verify.
Coverage
Code View | Wu Jian, Source Code Capital: Reassessing the Value of Manufacturing
MaHui | Keya Medical Accelerates Global Expansion with World's First AI Product Certified by China, Europe, and the United States
will be a milestone event in the development of AI healthcare in China
"The Tech + Biotech" Crossover: A New Investment Consensus on Convergent Innovation
Professional, systematic, and patient for the long haul.
Source Code Capital's Xingshi Wang and Yungang Huang Named MVIP Young Investors of the Year and Best Digital Healthcare Investor
MVIP of the Year, Best Investor in Digital Healthcare.
